MIMETAS

Are you looking to elevate your toxicity research? At MIMETAS, we advance your compound profiling and screening through complex, human-relevant assays for high-throughput toxicity assessments. Our 3D human tissue models are developed to provide you with accurate, reliable, and actionable data, supporting the development of more effective therapies. 💡 Swipe through to get inspired by some of our toxicity applications and offerings. Discover how MIMETAS can support your specific preclinical research needs: https://lnkd.in/ewYbgQ5c #ToxicityResearch #CompoundProfiling #HighThroughputScreening #OrganOnAChip

Today marks our last day of the MasterClass in Amsterdam where we get inspired by the amazing technologies of intestine on a chip! Missed this one? Visit our website for the upcoming events: https://lnkd.in/dxFsdWUk Should you use organ on a chip technology and if so how should you approach this? Yesterday we answered these questions through: -       Expert views by dr Jianbo Zhang and dr Sebo Withoff were we gain in-depth insights on ongoing intestine on a chip research -       Commercial session by MIMETAS and Dynamic42 GmbH where the different technologies are showcased. -       Organ on a chip Challenge where you develop your own organ on a chip assay And today we wrap up with the Organ on a chip Challenge presentations where we apply the knowledge to showcase organ on a chip assays that the participants develop from an idea to concrete plans. This always leads to fruitful and lively discussions and sometimes these ideas even go into execution! Follow us to stay up to date with upcoming MasterClasses and more!

Snapshots from Europe's largest neuroscience congress, Federation of European Neuroscience Societies - FENS Forum 2024, where cutting-edge research and innovation in neuroscience take center stage. Our Director of Biology Services, Nienke Wevers, had the pleasure of presenting our latest breakthroughs to an enthusiastic audience. 📊 We showcased two insightful posters: - "Blood-Brain Barrier On-A-Chip To Study Compound-Induced Disruption" - "Human BBB-On-A-Chip Reveals Barrier Disruption, Endothelial Inflammation, And T Cell Migration Under Neuroinflammatory Conditions" Nienke's presentations sparked engaging discussions on these critical areas of research, highlighting the advancements MIMETAS is making in understanding the complexities of the blood-brain barrier and neuroinflammation. 📥 Interested in diving deeper into our findings? Download our BBB app note here: https://lnkd.in/eReeHJQX #FENS2024 #Neuroscience #Research #BloodBrainBarrier #Neuroinflammation

Meet us at #ISSCR2024! Join us and over 4,000 scientists from around the world for the most significant advancements in stem cell research and regenerative medicine. Our team will be at booth #1116 where you can meet Naomi den Breems and Gwenaëlle Rabussier to explore discuss your specific needs and how our human relevant 3D tissue models can support your research. 💬 We invite you to schedule a meeting with them ahead of time! 📰 We'll also have a Poster #361: "Towards A High-Throughput Gut-On-Chip Model With Patient-Derived Colon Organoids For Phenotypic Evaluation Of Intestinal Epithelial Responses" 📅 Date: July 10, 2024 🕔 Time: 17:45 - 18:45 See you in Hamburg! https://lnkd.in/eTusg8A3 #StemCellResearch #Organoids #3DTissueModels #MicrophysiologicalSystems

🔬Research Spotlight! In collaboration with MIMETAS, researchers from GSK developed an advanced 3D chemotaxis assay in a lung tumor-on-chip model (LToC-Endo). This platform accurately mimics in vivo stromal and vascular barriers, enabling detailed studies of T-cell adhesion, extravasation, and migration. By integrating a T-cell activation protocol and examining ICAM-1 blocking effects, this model provides valuable insights for evaluating immune chemotaxis into tumors. This work underscores the potential for translational strategies to enhance personalized medicine and therapeutic development. Additionally, our assay supports the reduction, refinement, and replacement of animal models, paving the way for translational strategies leading to preclinical and clinical models to support human dose prediction, ethical and effective research methods. Read more about our research and its implications for future cancer treatments: https://lnkd.in/eMRE_heB #LungCancerResearch #DrugDevelopment #CancerResearch #OncologyResearch #CancerModels

"By harnessing the power of novel bio-micromanufacturing, we can create organ-chip models that are far more representative of the human body. This will revolutionise drug discovery, leading to safer, more effective therapies reaching patients faster." - Prof. Martin Knight Kudos, EPSRC! They've just funded a £1.7M project for developing more human #organchips for use in #drugdiscovery. 🧍💊 Congrats to the project teams at Queen Mary University of London, GSK, UCB, Emulate, Inc., CN Bio , MIMETAS, and the U.K. Medicines and Healthcare products Regulatory Agency https://lnkd.in/gtzAdw5A   #humanrelevantresearch #nonanimalmethods #NAMs #organonachip #organsonchips #microfluidics #funded #biotech

⏰ Last day to register for our live webinar! Tomorrow at 4 PM CET, Lenie van den Broek will share insights on phenotypic disease modeling for inflammation and how 3D disease models advance the discovery of immune-targeting therapies! 💡 What you'll learn: - Case study on mechanism of action and antibody ranking in vascular inflammation assays - Using complement activated serum in immune-competent renal models - Capturing key IBD mechanisms with adult stem cell-derived gut organoid models - Benefits of partnering with MIMETAS to accelerate your research and improve the selection of your immunomodulatory compounds 🔗 Register now: https://lnkd.in/gxbx_yaH #Webinar #DrugDiscovery #Inflammation #ImmuneTherapies #IBD

In this video, we feature the MIMETAS OrganoReady® Colon Organoid! This 3D Human Colon Organoid tubule, stained for tight junction (Occludin, green) and cell nuclei (blue), is the first ready-to-use adult stem cell-derived solution offered license-free for commercial use. We offer a fully characterized gastrointestinal model delivered straight to your lab, ensuring that it captures human intestinal processes and enables more accurate predictions of drug responses. Through our fee-for-services, we also build on top of this model in house, with the incorporation of other key cellular players and disease phenotypes at scale. In this upcoming webinar, learn how we capture the complexity of inflammatory bowel disease from multiple angles, enabling more accurate predictions of drug responses. Register for our live webinar: https://lnkd.in/edQbawru Learn more about the model: https://lnkd.in/egjYn_D6

Join us on Tuesday, June 25th, for a live webinar on Phenotypic Disease Modeling for Inflammation: Advancing Immune-targeting Therapies! Presented by Lenie van den Broek, Director Biology Discovery at MIMETAS, this webinar will dive into the complexities of immune-targeting therapies and how innovative 3D disease modeling is impacting drug discovery. 💡 What you'll learn: - Case study on mechanism of action and antibody ranking in vascular inflammation assays - Using complement activated serum in immune-competent renal models - Capturing key IBD mechanisms with adult stem cell-derived gut organoid models - Benefits of partnering with MIMETAS to accelerate your research and improve the selection of your immunomodulatory compounds - Be the first to learn about our new product, the OrganoReady® Colon Organoid 🔗 Register now: https://lnkd.in/edQbawru #Webinar #DrugDiscovery #Inflammation #ImmuneTherapies #3DModeling

Our partner, Astellas Pharma., has made a significant contribution to drug discovery research! In their latest study, published in the International Journal of Molecular Sciences MDPI, they showcase an nnovative human Blood-Brain Barrier (BBB) model using our OrganoPlate® platform. This research involves the development of a microfluidic human BBB-on-a-chip model designed to study barrier dysfunction and immune cell migration. The model demonstrates barrier integrity and tracks immune cell migration under various conditions. This model offers new insights into neurodegenerative and neuro-immunological diseases, enhancing our understanding of drug delivery mechanisms to the central nervous system (CNS). 👏 Congratulations to the Astellas Pharma Inc. team for this remarkable achievement! We are proud to support innovative research that pushes the boundaries of medical science. 🔗 Read the full publication here: https://lnkd.in/ebNMJfxk #DrugDiscovery #BloodBrainBarrier #InnovativeResearch #Pharma #NeuroScience